Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity

Résultats de recherche

• Actif

  Clinical Pharmacology Research Group

  Douxfils, J., Dogne, J., Musuamba Tshinanu, F., Masereel, B., Wieërs, G., Haguet, H., RONVAUX, L., Donis, N., Morimont, L., Evrard, J., Siriez, R., Gillot, C., FAVRESSE, J., BOUVY, C., Djokoto, H., Didembourg, M., David, C., Melchionda, S., Maloteau, V., Boucher, A., Devel, P., Modaffari, E., Vandeputte, M., De Messemaeker, A., Decarpentrie, J., Vassart, J. & De Groote, A.

  1/04/22 → …

  Projet: Axe de recherche

  • Neutralizing Antibody 100%
  • COVID-19 80%
  • Direct Oral Anticoagulant 79%
  • Severe Acute Respiratory Syndrome Coronavirus 2 78%
  • Patient 63%

• The COVILAB project : Clinical laboratory investigations related to COVID-19

  Douxfils, J., Dogne, J., FAVRESSE, J., Tre-Hardy, M., Mullier, F., Haguet, H., Hardy, M., Melchionda, S., BOUVY, C., Morimont, L., Gillot, C., Djokoto, H., Alpan, L., Devel, P., Modaffari, E. & Maloteau, V.

  13/03/20 → …

  Projet: Recherche

  • Severe Acute Respiratory Syndrome Coronavirus 2 100%
  • COVID-19 95%
  • Patient 81%
  • SARS Coronavirus 74%
  • Monospecific Antibody 72%